PXMBF Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EDT
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $3.50
Previous CloseN/A
Volume330.00
Average Volume (3M)0.00
Market Cap
$111.57M
Enterprise Value$1.02K
Total Cash (Recent Filing)$106.09M
Total Debt (Recent Filing)$4.58M
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
Aug 21, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding23,273,417
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)3.05
Price to Sales (P/S)3.95
P/FCF Ratio-76.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.19
Revenue Forecast (FY)$43.16M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong revenue expansion indicates increasing adoption of Paxman’s scalp-cooling platform and broader market reach. Continued growth can enlarge the installed base and support recurring consumable, service, and treatment-related revenue over the medium term.
Low LeverageVery low leverage limits interest burden and refinancing risk, giving Paxman greater flexibility to fund product development, commercial expansion, and customer deployments while it works to restore profitability and cash generation.
Recurring Revenue ModelThe combination of installed equipment, usage-linked consumables, and support services can create revenue beyond the initial system sale. A growing installed base may therefore improve customer retention and increase recurring revenue visibility.
Bears Say
Profitability DeteriorationThe shift from profit to loss weakens internal funding capacity and raises execution risk. Unless revenue growth translates into stronger operating leverage, ongoing losses could constrain investment and delay sustainable earnings recovery.
Negative Cash FlowNegative operating and free cash flow means expansion and working-capital needs are not currently funded by operations. If losses persist, Paxman may need to rely more heavily on its balance sheet or external financing.
Weak Capital ReturnsNegative returns on equity show that Paxman is not currently converting its capital base into attractive profits. This suggests that commercial scale has not yet translated into efficient shareholder returns and highlights the need for better margins.
Paxman AB News
PXMBF FAQ
What was Paxman AB’s price range in the past 12 months?
Paxman AB lowest stock price was $0.01 and its highest was $3.50 in the past 12 months.
What is Paxman AB’s market cap?
Paxman AB’s market cap is $111.57M.
When is Paxman AB’s upcoming earnings report date?
Paxman AB’s upcoming earnings report date is Aug 21, 2026 which is today.
How were Paxman AB’s earnings last quarter?
Currently, no data Available
Is Paxman AB overvalued?
According to Wall Street analysts Paxman AB’s price is currently Overvalued.
Does Paxman AB pay dividends?
Paxman AB does not currently pay dividends.
What is Paxman AB’s EPS estimate?
Paxman AB’s EPS estimate is 0.03.
How many shares outstanding does Paxman AB have?
Paxman AB has 23,273,417 shares outstanding.
What happened to Paxman AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Paxman AB?
Currently, no hedge funds are holding shares in PXMBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Paxman AB
Paxman AB (publ), along with its subsidiaries, specializes in the creation and worldwide sale of the Paxman scalp cooling system, an innovative solution designed to minimize hair loss in patients undergoing chemotherapy. This system is distributed across Europe, the United States, Mexico, Japan, Oceania, various Asian regions, and both South and Central America, primarily serving cancer centers and hospitals. The company is also engaged in a research collaboration agreement with the National University Hospital in Singapore, working towards the development of a portable cooling and compression device. Established in 1996, Paxman AB (publ) is headquartered in Karlshamn, Sweden.
PXMBF Earnings Call
Q2 2026
0:00 / 0:00
Technical Analysis
Senzime AB
―
Xvivo Perfusion AB
―
Bactiguard Holding AB
―
BrainCool AB
―
Sedana Medical AB
―